Christine M. Fandozzi

CHRISTINE M. FANDOZZI, PhD is associate vice president at Merck Research Laboratories in the department of pharmacokinetics, pharmacodynamics, and drug metabolism.  She leads the global bioanalytical group, the group responsible for the preclinical and clinical measurement of drug and immunogenicity across Merck’s entire portfolio.  In her previous role as executive director, she oversaw the operations, outsourcing, and logistics for the PPDM department. In that role, she built a strong business and operational acumen while managing the budget and overseeing external work in North America, Europe, and Asia. Previously, Fandozzi developed a broad understanding of drug discovery and development and a deep expertise in ADME science, having supported numerous discovery and development programs with a focus in antivirals and neuroscience.  She has extensively contributed to the discovery and development of the approved HCV anti-virals VANIPREVIR® and ZEPATIER® including product approvals in many major markets.  In her work she demonstrates integrity and ethics by respecting people, holding folks accountable, and communicating openly and candidly. Fandozzi earned BS in chemistry and biochemistry from La Salle University of Philadelphia, PA, and a PhD in chemistry from the University of Virginia, Charlottesville, VA. @merck